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After the 2006–2007 epidemic wave of Rift Valley fe-
ver (RVF) in East Africa and its circulation in the Comoros, 
laboratory case-ﬁ  nding of RVF was conducted in Mayotte 
from September 2007 through May 2008. Ten recent human 
RVF cases were detected, which conﬁ  rms the indigenous 
transmission of RFV virus in Mayotte.
R
ift Valley fever (RVF) is a zoonotic and mosquito-
borne disease that affects animals and humans (1). In 
humans, RVF infection is usually asymptomatic or charac-
terized by an acute self-limited febrile illness. However, in 
≈1%–3% of case-patients, it can cause serious manifesta-
tions that may lead to death or disabling sequelae in sur-
vivors (2,3). Identiﬁ  ed in the 1930s in Kenya, RVF virus 
(RVFV) circulates now in many other African countries 
(4–7), as well as on the Arabian peninsula (8), where epi-
zootics and associated human cases have been reported. 
In early 2007, RVF outbreaks were reported in sev-
eral eastern African countries (9). Additionally, in August 
2007, autochthonous RVF transmission was found on 
the Indian Ocean island of Grande Comore, Republic of 
Comoros. A young Comorian with a 2-month history of 
severe encephalitis was transferred from the Republic of 
Comoros to Mayotte, where diagnostic and medical care 
facilities are more readily available. Mayotte, a French ter-
ritory, is located northwest of Madagascar, in the Comoros 
archipelago (Figure). 
Anti-RVFV immunoglobulin (Ig) M was detected 
by IgM antigen-capture ELISA (10) in the serum sample 
of this patient. This sentinel event had substantial public 
health implications for Mayotte because the Republic of 
Comoros and Mayotte have frequent exchanges of popula-
tions and goods, both legally and illegally.
An active laboratory-based surveillance system for 
RVF was implemented for livestock in Mayotte in March 
2008, which has led to several recent RVF cases being de-
tected in cattle (Bureau of Veterinary Services, Mayotte, 
unpub. data). Subsequently, to assess the situation of RFV 
among humans, we retrospectively and prospectively ana-
lyzed serum specimens from febrile patients sampled by a 
routine surveillance program for chikungunya and dengue 
viruses. We describe the clinical, biological, and epidemio-
logic characteristics of human RVF cases in Mayotte. 
The Study
Since the 2005–2006 chikungunya outbreak (11), lab-
oratory-based surveillance of chikungunya virus (CHIKV) 
and dengue virus (DENV) is routinely maintained in May-
otte. Specimens are collected from patients attending local 
primary healthcare facilities or hospitals who seek treatment 
for dengue-like illness, i.e., acute onset of high fever ac-
companied by at least 2 of the following signs: arthralgia, 
body pain, headache, malaise, fatigue, or rash. Stored pa-
tient samples collected from September 2007–March 2008 
and prospective specimens from this system, which initially 
tested negative for CHIKV and DENV as well as for Plas-
modium spp. by using the rapid diagnostic test OptiMAL 
(Flow Inc., Portland, OR, USA), were screened for RVFV. 
We deﬁ  ned a conﬁ  rmed recent human case-patient as a 
person with dengue-like illness and the serum positive for 
anti-RVFV IgM by antigen-capture ELISA or RVFV RNA 
by reverse transcriptase–PCR (12). Any specimen positive 
when tested by the local reference laboratory was then for-
warded for conﬁ  rmation to the National Reference Centre 
for Arboviruses and the World Health Organization Col-
laborating Centre for Arboviruses, Pasteur Institute, Paris, 
France. Identiﬁ  ed case-patients were investigated by using 
a standardized form to gather information, particularly re-
garding exposure data, e.g., peridomestic environment, han-
dling of animal products, occupational exposures, and travel 
history. The relevant period of exposure was 3 weeks before 
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Figure. Location of Mayotte (boxed) in the Comoros Archipelago. 
Source: Préfecture de Mayotte.Rift Valley Fever, Mayotte
disease onset. Medical records of conﬁ  rmed case-patients 
were also reviewed if needed. Investigations were conduct-
ed in accordance with the French National Institute of Pub-
lic Health (Institut de Veille Sanitaire) guidelines for studies 
conducted in rapid response to public health threats. 
From September 1, 2007, through May 31, 2008, 220 
serum specimens from persons with dengue-like illness who 
tested negative for Plasmodium spp., CHIKV, and DENV 
were screened; recent RVFV infection (i.e., presence of vi-
ral RNA or IgM) was found in 10 samples (4.5%). The earli-
est recorded onset of dengue-like illness was September 27, 
2007, and the latest was May 14, 2008. Seven cases (70%) 
occurred from January through April, during the hot, rainy 
season (Table). Conﬁ  rmed case-patients were not clustered 
spatially and resided in the following counties: Mamoudzou 
(3), Bandraboua (2), Dembeni (1), Sada (1), Chirongui (2), 
and Boueni (1).
Of these conﬁ  rmed-case patients, 9 (90%) were male 
(age range 16–53 years, median 27.5 years), 5 (50%) were 
French citizens native to Mayotte, and 5 (50%) were Co-
morian citizens. None of the cases reported recent (i.e., 
within 3 weeks before onset of illness) travel into countries 
with RVF endemic transmission. 
Although 2 patients were admitted to the intensive care 
unit for medical management, no severe neurologic mani-
festations of RVF were observed, and no deaths could be 
attributed to RVF. Case-patient 6 (Table), with a coexisting 
condition of cirrhosis after hepatitis B infection, had sub-
stantial thrombopenia (< 40,000 cells/mm3) and died as a 
result of gastrointestinal bleeding and hepatic encephalopa-
thy. Case-patient 10 was admitted to the hospital in May 
2008 with a 5-day history of high body temperature, body 
pain, joint pain (particularly in the shoulders), and fatigue, 
combined with symptoms consistent with right-sided heart 
failure (shortness of breath, hepatomegaly, and peripheral 
edema). The patient was discharged with a diagnosis of 
pericarditis. He had a follow-up visit 1 month later, and a 
sample obtained on this occasion tested positive for RVFV 
IgM and IgG. 
Predictably, contact with ruminants (sheep, cattle, or 
goats) was the predominant means of exposure among re-
ported case-patients; this mode was documented in 5 of 9 
cases that were fully investigated. Furthermore, only the 
presence of numerous breeding sites for mosquitoes in the 
housing environment remained as a possible means of ex-
posure for 3 other case-patients. The mode of transmission 
remains undetermined for the remaining case-patient, who 
had no admitted direct contact with ruminants and whose 
housing environment did not have numerous breeding sites 
(Table). 
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Table. Epidemiologic, clinical, and laboratory findings of 10 case-patients with confirmed recent Rift Valley fever virus infection,
Mayotte, France, September 2007–May 2008* 
Case-
patient no. 
Age, y/sex, 
occupation
Identified source of 
exposure(s)  Onset date; early signs and symptoms  Laboratory findings 
1 47/M, gardener  Herding animals  2007 Sep 27; 1-day history of fever, arthralgia, 
body pain 
RT-PCR positive, AST 9N, 
ALT 4N 
2 42/F, shopkeeper Contact with 
aborted animal 
2008 Jan 5; 2-day history of fever, headache, 
malaise
RT-PCR positive 
3 21/M, unknown  Unknown  2008 Jan 19; chronic hepatitis B, 3-day-history 
of fever, arthralpgia, and headache 
RT-PCR positive, AST 4 N, 
ALT 3N, elevated CPK level, 
thrombocytopenia 
4 19/M, farmer and 
herder of animals 
Milked animal  2008 Jan 21; 2-day history of fever, joint pain, 
headache, malaise 
RT-PCR positive 
5 16/M, student  Killed and skinned 
sick animals 
2008 Jan 21; 2-day history of fever, joint pain, 
headache
RT-PCR positive 
6 44/M, unemployed  Mosquito breeding 
sites in rural 
household
2008 Mar 13; 2-day history of fever, body 
aches; hepatic encephalopathy 
RT-PCR positive (threshold 
values), RVF IgM positive 
7 19/M, student  Undetermined 2008 Mar 19; 1-day history of fever, myalgia, 
retro-orbital pain, joint pain, body aches, 
malaise
RT-PCR positive 
8 24/M, handyman  Numerous mosquito 
breeding sites in 
household
2008 Mar 28; 5-day history of fever, joint pain, 
myalgia, nausea/vomiting 
RT-PCR positive at 
threshold, RVF IgM positive, 
thrombocyopenia 
9 32/M, construction
worker 
Mosquito breeding 
sites in rural 
household
2008 May 5; 7-day history of fever, myalgia, 
joint and body pain, malaise 
RVF IgM positive, elevated 
ALT, AST, and CPK levels 
10 53/M, farmer  Slaughtering and 
butchering animals 
2008 May 14; 5-day history of fever, joint pain, 
body aches and symptoms of right-sided heart 
failure, discharge diagnosis of pericarditis; new 
episode of fever, fatigue, and shortness of 
breath 30 days later and screening for RVF 
RVF IgM positive 
*RT-PCR; reverse transcription–PCR;  AST, aspartate aminotransferase; N, upper limit of normal titers; ALT, alanine aminotransferase; CPK, creatine 
phosphokinase; RVF, Rift Valley fever; Ig, immunoglobulin. Conclusions 
The laboratory case-ﬁ  nding initiated in response to the 
2006–2007 RVFV outbreaks in eastern Africa found in-
digenous transmission in Mayotte. As a result, information 
was provided to the population, and preventive activities 
were undertaken, e.g., information for healthcare provid-
ers, a campaign to eliminate mosquito-breeding sites, rec-
ommendations to avoid contact with mosquitoes and sick 
animals, and instructions on adopting appropriate protec-
tive measures when engaging in activities related to ani-
mals, including slaughtering and butchering.
Because our investigations were mostly retrospective, 
we cannot exclude recall bias about exposure and incom-
plete documentation. Moreover, entomologic investiga-
tions in the living areas of the case-patients several months 
after the ﬁ  rst signs of illness occurrence were incomplete. 
RVF activity in Mayotte appears to be an expansion of 
the eastern Africa outbreak. As in the case of the chikun-
gunya outbreak in 2005–2006 in Mayotte, thought to have 
started in Lamu, Kenya (13), RVFV circulation illustrates 
once again the risk of introduction or circulation in Mayotte 
or other Comorian islands of infectious agents involved in 
outbreaks in neighboring eastern African coastal countries 
(14). This risk is particularly important because of the fa-
vorable climatic conditions and the presence in Mayotte of 
replication-competent vectors of numerous arboviruses.
This epidemic is a further illustration that it is imperative 
for healthcare providers, epidemiologists, and policy mak-
ers in Mayotte to remain alert each time there are outbreaks 
in nearby countries because the risk of extension to May-
otte is always plausible. Furthermore, the documentation 
of RVFV circulation in Mayotte should serve as a further 
impetus toward the development of surveillance programs 
for nonspeciﬁ  c febrile illnesses, especially in settings where 
arboviruses are highly prevalent. To achieve this objective, 
local laboratory capabilities should be enhanced to enable 
biological diagnosis of a wide array of arboviruses that ac-
tively circulate in the eastern African seaboard region. Fur-
thermore, medical education materials and feedback bulle-
tins should regularly provide information about accessing 
laboratory services while encouraging patients with febrile 
illness to seek early medical evaluation. Ultimately, main-
taining such programs is essential to promptly detecting 
any renewed introduction or resurgence of RVF and other 
pathogens, especially during the hot and rainy season.
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